title: Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD.
abstract: Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous disorder characterized by inappropriate levels of attention, hyperactivity, and impulsivity. Although a strong genetic component to the disorder has been established, the molecular genetic underpinnings of this disorder remain elusive. Recently, several studies have reported an association between polymorphisms within the latrophilin 3 gene (LPHN3) and ADHD. Interestingly, the same single-nucleotide polymorphism conferring susceptibility to ADHD has also been found to predict efficacy of stimulant medication in children. The main objectives of the current article are: (i) To tackle the phenotype heterogeneity issue in ADHD by defining an objective and quantitative measure of response to treatment in a sample of ADHD children based on a hand held automatic device (Actiwatch) and (ii) to use this measure to reproduce for the first time the association between LPHN3 variants and response to methylphenidate (MPH) using a double-blind, placebo-controlled crossover experimental design. The results of our study confirm the hypothesis that LPHN3 is associated with response to MPH in ADHD children. Although this will require further validation, our work suggests that the use of an objective measure of response to treatment, such as the change in the child's motor activity measured by Actiwatch, has the potential to uncover genetic association signals that in some conditions might not be obtained using more subjective measures, such as the clinical consensus rating, for example.
authors.affiliation: Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada. aurelie.labbe@mcgill.ca
authors.forename: Aurelie
authors.initials: A
authors.lastname: Labbe
authors.forename: Andy
authors.initials: A
authors.lastname: Liu
authors.forename: Juli
authors.initials: J
authors.lastname: Atherton
authors.forename: Natalie
authors.initials: N
authors.lastname: Gizenko
authors.forename: Marie-Ève
authors.initials: MÈ
authors.lastname: Fortier
authors.forename: Sarojini M
authors.initials: SM
authors.lastname: Sengupta
authors.forename: Joober
authors.initials: J
authors.lastname: Ridha
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology*; D002648:Child; D018592:Cross-Over Studies; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D010641:Phenotype; D011110:Polymorphism, Genetic; D043562:Receptors, G-Protein-Coupled / Q000235:genetics*; D018000:Receptors, Peptide / Q000235:genetics*
chemical_list: C513284:ADGRL3 protein, human; D018765:Dopamine Uptake Inhibitors; D043562:Receptors, G-Protein-Coupled; D018000:Receptors, Peptide; D008774:Methylphenidate